Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962039 · ClinicalTrials.gov registry record · Phase 2
Anxiety and Recurrent Abdominal Pain in Children
A Phase 2 study of Anxiety and Abdominal Pain, sponsored by John V. Campo, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT00962039: Completed Phase 2 study of Anxiety and Abdominal Pain, sponsored by John V. Campo, M.D..
NCT00962039 is a Phase 2 study of Anxiety and Abdominal Pain that has completed, run by John V. Campo, M.D.. The registered enrollment target is 81 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00962039, a Phase 2 study of Anxiety and Abdominal Pain, has completed, sponsored by John V. Campo, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine whether citalopram is a useful, well-tolerated, and safe treatment for children and adolescents ages 7 to 18 years with functional abdominal pain. The study hypothesis is that citalopram will be better than placebo in producing clinical improvement and reductions in abdominal pain. It is also hypothesized that citalopram and placebo will not differ in terms of safety and tolerability.
Primary Outcome
Clinical Global Impression Scale - Improvement (CGI-I) is a 7-point scale, with lower values being more favorable, used to assess overall global illness improvement. The CGI is a clinician-completed measure, with values ranging from 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), to 7 (very much worse). CGI-I scores of 1 (very much improved) or 2 (much improved) were considered to indicate an acceptable treatment response. A
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Citalopram
Study Locations (1)
Ohio
- The Research Institute at Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00962039 record still lists
NCT00962039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00962039 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00962039 about?
NCT00962039 is a clinical study titled "Anxiety and Recurrent Abdominal Pain in Children". This study aims to determine whether citalopram is a useful, well-tolerated, and safe treatment for children and adolescents ages 7 to 18 years with functional abdominal pain. The study hypothesis is that citalopram will be better than placebo in producing clinical improvement and reductions in abdo...
What is the current status of trial NCT00962039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2004-07. Estimated completion is 2010-04.
What conditions does trial NCT00962039 study?
This clinical trial studies the following conditions: Anxiety, Abdominal Pain.
What interventions are being tested in trial NCT00962039?
The interventions under investigation include: Placebo (DRUG), Citalopram (DRUG).
Who is sponsoring clinical trial NCT00962039?
This trial is sponsored by John V. Campo, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00962039 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00962039's enrollment target sits among peer trials
81 195th of 364 higher than 170 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Use of CBD in the Treatment of Anxiety
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia